Wegovy Users Maintain Weight Loss for 4 Years: Here's How It Works

Updated Dec 3, 2024 | 09:00 PM IST

SummaryWegovy, is primarily an antidiabetic medication used to treat Type 2 diabetes. People receiving weight-loss drug Wegrovy sustained weight loss for up to four years
wegovy

wegovy (Credit: Canva)

People receiving weight-loss drug Wegovy sustained weight loss for up to four years, shedding an average of 10% of their body weight in that time, as per a new study. Wegrovy is a brand that markets semaglutide injections, that have gained widespread attention for their weight-loss effects. The study also found that Semaglutide injections boost an individual's heart health, even when weight loss doesn't take place.

The study, called SELECT, was published in journal Nature Medicine. "At four years, we see ongoing benefits of semaglutide," said Cheng-Han Chen, MD, interventional cardiologist from Cardiologist, who was not involved in the research. Besides the weight loss, it also lead to a loss in cardiovascular outcomes.

The research was conducted on 17000 adults, who had obesity but did not have diabetes. Overall, people who received once-weekly injections of semaglutide lost on average 10.2% of their body weight over the course of four years. All of the study participants continued to lose weight for about 65 weeks, a year and three months, and then their weight remained at a stable level.

Were There Any Side Effects?

However, people's experience with the medication varied. Researchers found no unexpected safety issues with drug during trial. In fact, most the people who withdrew from the study were those who experienced the known symptsoms of the semaglutide injections like nausea, indigestion etc. This occurred mainly during the beginning of the study, as the dose of the medicine is increased to a maximally tolerated dose.

What Did The Results Say?

Of the people on the highest dose of Wegovy, 68% lost at least 5% of their body weight. This compared to 21% of people on the placebo. Additionally, of the total people on Wegovy about 23% lost at least 15% of their body weight. For those in the placebo group, only 1.7% lost that much body weight.

Semaglutide Shows Heart Benefits Beyond Weight Loss

Researchers found that even individuals who did not experience significant weight reduction while on the drug saw a reduced risk of major heart events. Recent analysis of the SELECT trial data revealed that semaglutide significantly lowers the risk of heart attack, stroke, and cardiovascular-related deaths in adults with obesity or those who are overweight. Notably, the results of this study lead the US FDA to approve Novo Nordisk's Wegovy for reducing heart-related risks in this group.

What Is Semaglutide?

Semglutide is the synthetic version of GLP-1—a natural hormone produced in the intestines that regulates blood sugar, appetite, and digestion. Now, every time you eat, your body produces various hormones, including GLP-1. These are called Post nutrition hormones, and help you absorb the energy you just consumed. GLP-1 travels to your pancreas, prompting it to produce insulin. It also travels to the hypothalamus in your brain, which gives you the feeling of being full or satiated. Ozempic imitates this hormone, thereby, silencing the food chatter in the brain. Interestingly, for some people this food chatter is really quiet ( people with low appetite) and for others it is an outburst, (people who generally binge eat.) So with Ozempic, silencing this self-talk in the brain, people tend to lose their appetite and eventually weight.

Are Their Any Side Effects Of Semaglutide?

Semaglutide, marketed under the brand name Wegovy, is primarily an antidiabetic medication used to treat Type 2 diabetes. It is also an anti-obesity drug used for long-term weight management. While it can be taken as a subcutaneous injection or orally, it has significant side effects. It primarily impacts your gastrointestinal tract and its side effects include constipation, nausea, abdominal pain, diarrhoea, and fatigue amongst others.

End of Article

Yoga Shows Promise for Anxiety Relief And Seizure Control In Epilepsy, Claims AIIMS Study

Updated Jun 12, 2026 | 04:48 PM IST

SummaryThe study found that yoga reduced the burden of epilepsy and improved the overall quality of life in epilepsy patients by reducing the perceived stigma.
Yoga Shows Promise for Anxiety Relief And Seizure Control In Epilepsy, Claims AIIMS Study

Credit: Canva

Epilepsy is one of the most common neurological disorders and a leading cause of disability worldwide. Research has suggested that associated conditions, such as stigma, anxiety, and depression, can sometimes be more debilitating than the seizures themselves.

Stigma related to epilepsy can exist at both societal and individual levels, with many patients experiencing feelings of shame, fear, discrimination, and social isolation.

Now, research led by AIIMS New Delhi has suggested that yoga may help reduce epilepsy-related stigma while also improving seizure control. The 2023 study, published in Neurology, found that yoga-based interventions may offer benefits for both mental well-being and disease management.

“Yoga has been clinically proven to reduce the ‘felt stigma’ associated with epilepsy. By alleviating anxiety and improving both mindfulness and overall quality of life, mind-body interventions empower individuals to feel more in control and less socially isolated,” lead author Dr. Manjari Tripathi, Head of the Department of Neurology at AIIMS, told HealthandMe.

What Did the Study Find?

According to Dr. Manjari, the study identified three key benefits of yoga for people living with epilepsy:

  • Stigma Reduction: Patients who participated in a six-month yoga and psychoeducation program reported a significant reduction in perceived stigma compared with the control group.

  • Improved Seizure Control: The yoga intervention was associated with a higher rate of seizure reduction. "Participants were more than four times as likely to experience a greater than 50% reduction in seizures and were significantly more likely to achieve complete seizure remission," Dr. Manjari told HealthandMe.

  • Better Mental Health: Yoga practice was linked to lower anxiety levels, improved emotional regulation, and reduced cognitive impairment.

Also read: Yoga's Increasing Role As Great Soft Power And Preventive Healthcare: Ayush Secretary

Dr. Rajesh Sagar, Professor of Psychiatry at AIIMS, told HealthandMe that yoga reduced the burden of epilepsy and improved the overall quality of life in epilepsy patients by reducing the perceived stigma. The overall quality of life was also improved in the yoga group.

How Was the Study Conducted?

Read More: Congo Ebola Cases Rise to 676; FIFA World Cup Team Arrives in US After Quarantine

Researchers conducted a randomized clinical trial involving 160 adults with epilepsy who were followed for six months. Participants were assigned either a structured yoga program or a sham yoga intervention, while both groups also received epilepsy-related psychoeducation.

The yoga program included loosening exercises , breathing techniques, meditation, and positive affirmations.

While the impact on seizure frequency was reduced compared with the control group, the researchers cautioned that larger studies are needed to conclusively determine the effect of yoga on seizure control.

Yoga For Mental Health

Further, mood disturbances have been common among people with epilepsy and often remain inadequately addressed, particularly in developing countries.

According to the researchers, yoga may offer a scalable and accessible option for helping patients manage these challenges alongside conventional treatment.

Dr. Rajesh further told HealthandMe that yoga has well-established benefits for mental health.

“Yoga is important in mental health care, and it has been found that the three important things, which are pranayama, that is, breathing techniques, asanas, that is, physical posture, and dhyana, that is, meditation, have a positive effect on anxiety and even depression, and also improve sleep".

He added that yoga can help reduce stress, improve mood, lower anxiety levels, and enhance sleep quality.

“There is substantial evidence from around the world showing that yoga can benefit people living with certain mental health disorders,” he said.

End of Article

Beyond The Cuff: Why Uncontrolled Hypertension Deserves Urgent Attention

Updated Jun 12, 2026 | 11:54 AM IST

SummaryHypertension affects approximately 1.4 billion adults worldwide. Studies suggest that almost 54% of Indian patients have uncontrolled hypertension even while taking ≥2 medications.
Beyond The Cuff: Why Uncontrolled Hypertension Deserves Urgent Attention

Credit: iStock

Every morning, millions begin their day with a quick breakfast and blood pressure (BP) medication swallowed mechanically. But what happens when BP remains uncontrolled despite medicines? Uncontrolled hypertension is one of the most underestimated health threats. Often called the silent killer, it quietly damages the heart, brain, kidneys, and blood vessels.

The BP reading on the cuff captures only a visible measurement. BP that remains above goal over time despite treatment is concerning. Hypertension affects approximately 1.4 billion adults worldwide. Studies suggest that almost 54% of Indian patients have uncontrolled hypertension even while taking ≥2 medications. Thus, treatment does not necessarily mean control.

Why Does BP Control Matter?

Global organizations recommend stricter BP targets, aiming for readings below 130/80 mmHg or even 120 mmHg if tolerated. Studies show that each 10 mmHg reduction in systolic BP can decrease the risk of major cardiovascular events by 20%, stroke by 27%, heart failure by 28%, and death by 13%.

On the other hand, uncontrolled hypertension increases the risk of heart attacks, strokes, heart failure, end-stage kidney disease, type 2 diabetes, and death.

But What If The Numbers Don’t Change Despite Medication?

In persistently uncontrolled hypertension that other causes cannot explain, a hidden culprit called aldosterone is an under-recognized driver. Normally, aldosterone balances sodium and water to regulate BP.

However, in patients with uncontrolled hypertension, aldosterone production may remain abnormally high, causing sodium and fluid buildup, increasing BP.

Approximately 30% of patients with hypertension may have aldosterone dysregulation, and patients with resistant hypertension, obesity, type 2 diabetes, sleep apnea, and hypokalemia are at greater risk. Nearly 10–20% of patients with hypertension are treatment resistant, increasing their risk. In these patients, aldosterone dysregulation could be an important cause.

It is time to look beyond the cuff, as uncontrolled hypertension is a chronic, progressive, and often silent condition with serious consequences. Improving patient outcomes requires greater urgency, earlier intervention, better treatment optimization, and stronger awareness of underlying drivers such as aldosterone.

It is time to identify and treat the root causes of uncontrolled hypertension, so that patients can regain lasting BP control.

End of Article

Scientists Finally Have Answers To What Causes Inflammatory Bowel Disease

Updated Jun 11, 2026 | 05:00 PM IST

SummaryThe findings, published in the New England Journal of Medicine, suggest that inflammatory bowel disease is not a single condition but a group of biologically distinct diseases driven by different underlying mechanisms.
Scientists Finally Have Answers To What Causes Inflammatory Bowel Disease

Credit: Canva

Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, affects millions of people worldwide. The lifelong condition commonly begins in adolescence or early adulthood and can require repeated hospital treatment, long-term immunosuppressive medication, and, in some cases, surgery.

Despite advances in treatment, many patients cycle through multiple therapies without achieving lasting disease control, impacting their lives and costing healthcare systems millions.

Now, a team of UK researchers from the Universities of Oxford, Newcastle, and Cambridge has identified an important driver of inflammatory bowel disease (IBD).

The findings, published in the New England Journal of Medicine, suggest that inflammatory bowel disease is not a single condition but a group of biologically distinct diseases driven by different underlying mechanisms.

"Understanding what drives the inflammation provides a clear explanation for disease in this group of people and opens the door to new treatments that target the autoantibodies themselves or cells that produce those autoantibodies," said Professor Holm Uhlig, a pediatric gastroenterologist and director of the Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford.

What Did the Study Find?

Also read: Alcohol Study Shelved By Trump Administration Published In Scientific Journal: What Did It Find?

The researchers analyzed more than 4,900 patients with IBD and discovered that:

  • A substantial subset of patients shows autoimmune responses to one of the guardians of the immune system, interleukin-10 (IL-10), which leads to uncontrolled inflammation.
  • This damaging immune response is the mechanism for one of the strongest known genetic risk factors for IBD.

Antibodies that block interleukin-10 (IL-10), a cell-to-cell messenger that normally acts as one of the body's key controls on inflammation, effectively remove the immune system's natural "brake" on inflammation, allowing inflammatory responses to continue unchecked.

The researchers found high levels of anti-IL-10 neutralizing autoantibodies in the blood of about 3.5% of IBD patients, including those with Crohn's disease and ulcerative colitis, but not in healthy individuals. This could equate to 15,000–20,000 people with IBD in the UK carrying these autoantibodies.

The Genetic Link

Read More: US FDA Approves First New Sunscreen Ingredient Since the 1990s

The researchers also found that the presence of these antibodies was strongly linked to carriage of a particular genetic variant known as HLA-DRB1*01:03.

The link between HLA-DRB1*01:03 and a severe form of inflammatory bowel disease was first identified by Oxford researchers 30 years ago.

The new findings show that people carrying this variant are far more likely to develop antibodies that block IL-10, helping explain how the gene contributes to disease.

What Could This Mean for Patients?

The researchers say the findings support the development of a blood test to identify this subgroup of patients, helping clinicians move quickly toward more appropriate treatment.

What Is IBD?

As per the Centers for Disease Control and Prevention (CDC), IBD refers to a group of lifelong diseases that affect your intestines. The main types of IBD are ulcerative colitis and Crohn's disease.

Ulcerative colitis affects the large intestine, while Crohn’s disease can inflame any part of the digestive tract. Both are lifelong conditions of unknown cause that trigger abdominal pain, diarrhea and other complications, with no known cure.

What Are The Symptoms Of IBD That People Usually Ignore?

  • Diarrhea or changes in bowel movements
  • Stomach pain
  • Fatigue
  • Nausea
  • Weight loss
IBD can also lead to overall health complications, such as

  • Dehydration
  • Increased risk of colon and rectal cancers
  • Low red blood cell count (anemia)
  • Reduced bone density
  • Joint pain
  • Skin changes
  • Eye irritation
  • Delayed or impaired growth in some children.

End of Article